Anti-DOC2A monoclonal antibody

Pre-made anti-DOC2A monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to DOC2A/DOC2A products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP2461-Ab-1/ GM-Tg-hg-IP2461-Ab-2Anti-Human DOC2A monoclonal antibodyHuman
GM-Tg-rg-IP2461-Ab-1/ GM-Tg-rg-IP2461-Ab-2Anti-Rat DOC2A monoclonal antibodyRat
GM-Tg-mg-IP2461-Ab-1/ GM-Tg-mg-IP2461-Ab-2Anti-Mouse DOC2A monoclonal antibodyMouse
GM-Tg-cynog-IP2461-Ab-1/ GM-Tg-cynog-IP2461-Ab-2Anti-Cynomolgus/ Rhesus macaque DOC2A monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP2461-Ab-1/ GM-Tg-felg-IP2461-Ab-2Anti-Feline DOC2A monoclonal antibodyFeline
GM-Tg-cang-IP2461-Ab-1/ GM-Tg-cang-IP2461-Ab-2Anti-Canine DOC2A monoclonal antibodyCanine
GM-Tg-bovg-IP2461-Ab-1/ GM-Tg-bovg-IP2461-Ab-2Anti-Bovine DOC2A monoclonal antibodyBovine
GM-Tg-equg-IP2461-Ab-1/ GM-Tg-equg-IP2461-Ab-2Anti-Equine DOC2A monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP2461-Ab-1/ GM-Tg-hg-IP2461-Ab-2; GM-Tg-rg-IP2461-Ab-1/ GM-Tg-rg-IP2461-Ab-2;
GM-Tg-mg-IP2461-Ab-1/ GM-Tg-mg-IP2461-Ab-2; GM-Tg-cynog-IP2461-Ab-1/ GM-Tg-cynog-IP2461-Ab-2;
GM-Tg-felg-IP2461-Ab-1/ GM-Tg-felg-IP2461-Ab-2; GM-Tg-cang-IP2461-Ab-1/ GM-Tg-cang-IP2461-Ab-2;
GM-Tg-bovg-IP2461-Ab-1/ GM-Tg-bovg-IP2461-Ab-2; GM-Tg-equg-IP2461-Ab-1/ GM-Tg-equg-IP2461-Ab-2
Products NameAnti-DOC2A monoclonal antibody
Formatmab
Target NameDOC2A
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-DOC2A monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP2461-Ag-1Recombinant multi-species DOC2A/ Doc2 protein


    Target information

    Target IDGM-IP2461
    Target NameDOC2A
    Gene ID8448,13446,65031,707895,489945,101100270,528120,100066024
    Gene Symbol and SynonymsDoc2,DOC2A
    Uniprot AccessionQ14183,P70611
    Uniprot Entry NameDOC2A_HUMAN,DOC2A_RAT
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000149927
    Target ClassificationN/A

    The target: DOC2A, gene name: DOC2A, also named as Doc2. There are at least two protein isoforms of the Double C2 protein, namely alpha (DOC2A) and beta (DOC2B), which contain two C2-like domains. DOC2A and DOC2B are encoded by different genes; these genes are at times confused with the unrelated DAB2 gene which was initially named DOC-2. DOC2A is mainly expressed in brain and is suggested to be involved in Ca(2+)-dependent neurotransmitter release. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Aug 2013].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.